Lakefront Biotherapeutics | GLPG - Ebitda


Lakefront Biotherapeutics reported EUR-63.7M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
argenx SE USD 404.12M 17.08M Dec/2025
AstraZeneca USD 5.67B 1.29B Mar/2026
Biogen USD 649.7M 76.5M Mar/2026
Genmab DKK 186M 291M Dec/2025
Gilead Sciences USD 3.02B 1.01B Dec/2025
GlaxoSmithKline GBP 2.77B 1.65B Mar/2026
GRIFOLS EUR 347.45M 210K Dec/2025
Hikma Pharmaceutical USD 369M 84M Dec/2024
Incyte USD 367.97M 46.53M Mar/2026
Merck EUR 1.53B 87M Mar/2026
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Novartis USD 5.3B 530M Mar/2026
Roche Holding CHF 12.68B 2.36B Jun/2024
Sanofi EUR 3.31B 3.65B Mar/2026
UCB EUR 1.6B 570M Dec/2025
Vertex Pharmaceuticals USD 1.19B 195.3M Mar/2026